WO1998022500A3 - Modulation d'interactions entre myosine et integrines - Google Patents

Modulation d'interactions entre myosine et integrines Download PDF

Info

Publication number
WO1998022500A3
WO1998022500A3 PCT/US1997/022422 US9722422W WO9822500A3 WO 1998022500 A3 WO1998022500 A3 WO 1998022500A3 US 9722422 W US9722422 W US 9722422W WO 9822500 A3 WO9822500 A3 WO 9822500A3
Authority
WO
WIPO (PCT)
Prior art keywords
myosin
integrins
agents
block integrin
interactions
Prior art date
Application number
PCT/US1997/022422
Other languages
English (en)
Other versions
WO1998022500A9 (fr
WO1998022500A2 (fr
Inventor
Alison L Jenkins
David R Phillips
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Priority to AU55951/98A priority Critical patent/AU5595198A/en
Priority to EP97952309A priority patent/EP0942931A2/fr
Priority to CA002271935A priority patent/CA2271935A1/fr
Priority to JP52402098A priority patent/JP2001506595A/ja
Priority to NZ335932A priority patent/NZ335932A/en
Publication of WO1998022500A2 publication Critical patent/WO1998022500A2/fr
Publication of WO1998022500A9 publication Critical patent/WO1998022500A9/fr
Publication of WO1998022500A3 publication Critical patent/WO1998022500A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Reduction Or Emphasis Of Bandwidth Of Signals (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Transmission Systems Not Characterized By The Medium Used For Transmission (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)

Abstract

La présente invention décrit une interaction directe entre la myosine et le domaine cytoplasmique de protéines membranaires, en particulier les domaines cytoplasmiques phosphorylés de la sous-unité β d'intégrines. L'invention concerne des méthodes d'identification d'agents bloquant la liaison d'intégrine à la myosine; des méthodes d'utilisation d'agents bloquant la liaison d'intégrine à la myosine afin de moduler des procédés biologiques et pathologiques; et des agents bloquant la liaison assistée d'intégrine à la myosine, modulant ainsi le déplacement associé d'une cellule ou d'un composant cellulaire.
PCT/US1997/022422 1996-11-21 1997-11-21 Modulation d'interactions entre myosine et integrines WO1998022500A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU55951/98A AU5595198A (en) 1996-11-21 1997-11-21 Modulation of interactions between myosin and integrins
EP97952309A EP0942931A2 (fr) 1996-11-21 1997-11-21 Modulation d'interactions entre myosine et integrines
CA002271935A CA2271935A1 (fr) 1996-11-21 1997-11-21 Modulation d'interactions entre myosine et integrines
JP52402098A JP2001506595A (ja) 1996-11-21 1997-11-21 ミオシンとインテグリンとの間の相互作用の調節
NZ335932A NZ335932A (en) 1996-11-21 1997-11-21 Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3166596P 1996-11-21 1996-11-21
US60/031,665 1996-11-21
US4209397P 1997-03-28 1997-03-28
US60/042,093 1997-03-28
US97565397A 1997-11-21 1997-11-21
US08/975,653 1997-11-21

Publications (3)

Publication Number Publication Date
WO1998022500A2 WO1998022500A2 (fr) 1998-05-28
WO1998022500A9 WO1998022500A9 (fr) 1998-08-20
WO1998022500A3 true WO1998022500A3 (fr) 1998-10-15

Family

ID=27363931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022422 WO1998022500A2 (fr) 1996-11-21 1997-11-21 Modulation d'interactions entre myosine et integrines

Country Status (5)

Country Link
EP (1) EP0942931A2 (fr)
JP (1) JP2001506595A (fr)
AU (1) AU5595198A (fr)
NZ (1) NZ335932A (fr)
WO (1) WO1998022500A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865449B2 (en) 2003-11-19 2014-10-21 Danisco Us Inc. Multiple mutation variants of serine protease

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
SE9902056D0 (sv) 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
WO2001079144A2 (fr) * 2000-04-14 2001-10-25 Cor Therapeutics, Inc. Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine
WO2005052146A2 (fr) 2003-11-19 2005-06-09 Genencor International, Inc. Serine proteases, acides nucleiques codants pour les enzymes a serine et vecteurs et cellules hotes les contenant
CA2629715C (fr) 2005-11-18 2016-05-03 Glenmark Pharmaceuticals S.A. Anticorps anti-integrine alpha-2 et leurs utilisations
EP2068877A4 (fr) * 2006-07-19 2011-09-21 Cleveland Clinic Foundation Composés et méthodes de modulation de l'angiogenèse
US7618801B2 (en) 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025173A1 (fr) * 1994-03-14 1995-09-21 The Scripps Research Institute Procede d'identification d'inhibiteurs d'activation de l'integrine
WO1995034641A1 (fr) * 1994-06-15 1995-12-21 The Scripps Research Institute Modeles structurels pour domaines cytoplasmiques de recepteurs transmembranaires
US5498649A (en) * 1993-05-18 1996-03-12 Thiokol Corporation Low density thermoplastic elastomeric insulation for rocket motors
WO1997014432A1 (fr) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation de la transduction d'un signal induit par l'integrine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498649A (en) * 1993-05-18 1996-03-12 Thiokol Corporation Low density thermoplastic elastomeric insulation for rocket motors
WO1995025173A1 (fr) * 1994-03-14 1995-09-21 The Scripps Research Institute Procede d'identification d'inhibiteurs d'activation de l'integrine
WO1995034641A1 (fr) * 1994-06-15 1995-12-21 The Scripps Research Institute Modeles structurels pour domaines cytoplasmiques de recepteurs transmembranaires
WO1997014432A1 (fr) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation de la transduction d'un signal induit par l'integrine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAW DA ET AL: "Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine *phosphorylation* induced by platelet aggregation.", J BIOL CHEM, MAY 3 1996, 271 (18) P10811-5, UNITED STATES, XP002062627 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865449B2 (en) 2003-11-19 2014-10-21 Danisco Us Inc. Multiple mutation variants of serine protease

Also Published As

Publication number Publication date
JP2001506595A (ja) 2001-05-22
NZ335932A (en) 2001-03-30
EP0942931A2 (fr) 1999-09-22
AU5595198A (en) 1998-06-10
WO1998022500A2 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
DE69813158T2 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
WO1999036550A3 (fr) Molecules de proteases humaines
DE59908887D1 (de) Verfahren zur ein- bzw. abschaltung von verbrauchern
EP2330197A3 (fr) Agents antagonistes de liaison sélective de protéine de liaison d'ostéoprotégérine
CA2063822A1 (fr) Methode de modulation de l'expression genique par la transcription et de decouverte de substances chimiques pouvant servir de modulateurs de l'expression genique
WO2001077687A3 (fr) Ligands de fixation au prion et procedes d'utilisation correspondants
DE59709027D1 (de) Verwendung von polymerisatdispersionen als bindemittel für dichtungs- oder beschichtungsmassen
NO980198L (no) Modulatorer av funksjonen til FAS-reseptorer og andre proteiner
WO1998022500A3 (fr) Modulation d'interactions entre myosine et integrines
WO1999065935A3 (fr) Peptides et anticorps fas pour moduler l'apoptose
WO1999054728A3 (fr) Methode permettant de prevoir la capacite de composes de moduler l'activite biologique de recepteurs
WO1997026331A3 (fr) Utilisation de la proteine inhibitrice d'apoptose neuronale (naip)
WO1999033981A3 (fr) Proteines contenant des sequences-signaux humaines
MX9704546A (es) MODULACION DE LA TRANSDUCCION DE SEñALES MEDIADA POR INTEGRINAS.
WO2001079144A3 (fr) Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine
WO2002055725A3 (fr) Acides nucleiques, methodes et cellules transformees destinees a moduler la production de gibberelline
WO1999010741A3 (fr) Procedes et reactifs permettant d'identifier les modulateurs de l'apoptose neuronale
AP9901510A0 (en) Polypeptides comprising gax protein domains, involved in repressing transcription and or interacting with other proteins corresponding nucleic acids andtheir use.
WO2002006463A3 (fr) Regulation d'expression genique a l'aide de commutateurs polypeptidiques monomeres a chaine unique dependant d'un ligand
WO2000023602A3 (fr) Materiaux et methodes impliquant des domaines de retention conditionnelle
AU5571998A (en) Chimeric target molecules having a regulatable activity
WO1999028465A3 (fr) Molecules pias reconnaissant et fixant les proteines stat et procedes d'utilisation
WO2001020335A3 (fr) Procedes de modulation de la proliferation cellulaire
WO2001094952A3 (fr) Methodes et compositions permettant de moduler le transport des ldl oxydees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

COP Corrected version of pamphlet

Free format text: PAGES 1-36, DESCRIPTION, REPLACED BY NEW PAGES 1-32; PAGES 37-41, CLAIMS, REPLACED BY NEW PAGES 33-37; PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2271935

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004706

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 524020

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 335932

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 55951/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997952309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997952309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997952309

Country of ref document: EP